Update date
31 Mar 2025
Shareable Research Card
SpringWorks Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
This metric view shows SpringWorks Therapeutics, Inc. increase (decrease) in accounts receivable history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q1 2025
- Latest reported value
- $5,891,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Mar 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q1 2025.
- Latest reported value on this page: $5,891,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Increase (Decrease) in Accounts Receivable
Latest reported increase (decrease) in accounts receivable: $5,891,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q1 2025
SEC-backed company facts were refreshed from filings filed on 09 May 2025.
Benchmark Context
How Increase (Decrease) in Accounts Receivable compares with peers
SpringWorks Therapeutics, Inc. is outside the visible top 120 companies for increase (decrease) in accounts receivable in the current sample.
Compared with
Compared with 120 companies reporting increase (decrease) in accounts receivable in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Increase (Decrease) in Accounts Receivable is down about 161% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Mar 2012 to 31 Mar 2026.
- Nearby companies in this sample: NVIDIA CORP and Robinhood Markets, Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
SpringWorks Therapeutics, Inc.: Increase (Decrease) in Accounts Receivable
Latest period: Q1 2025. Period end: 31 Mar 2025. Units: USD. Frequency: quarterly and annual.
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Metric Snapshot
- Latest value
- $5,891,000
- Coverage range
- 31 Dec 2021 - 31 Mar 2025
- Fact rows
- 7
What This Metric Tells You
- Shows the reported level of increase (decrease) in accounts receivable over 31 Dec 2021 - 31 Mar 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 7 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Increase (Decrease) in Accounts Receivable levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | NVIDIA CORP (nvda) | $15,399,000,000 | Year - 25 Jan 2026 | Open NVIDIA CORP Increase (Decrease) in Accounts Receivable |
| 2 | Robinhood Markets, Inc. (hood) | $9,106,000,000 | Year - 31 Dec 2025 | Open Robinhood Markets, Inc. Increase (Decrease) in Accounts Receivable |
| 3 | Alphabet Inc. (googl) | $8,779,000,000 | Year - 31 Dec 2025 | Open Alphabet Inc. Increase (Decrease) in Accounts Receivable |
| 4 | Salesforce, Inc. (crm) | $8,632,000,000 | Quarter - 31 Jan 2026 | Open Salesforce, Inc. Increase (Decrease) in Accounts Receivable |
| 5 | Dell Technologies Inc. (dell) | $7,022,000,000 | Year - 30 Jan 2026 | Open Dell Technologies Inc. Increase (Decrease) in Accounts Receivable |
| 6 | ARROW ELECTRONICS, INC. (arw) | $6,342,006,000 | Year - 31 Dec 2025 | Open ARROW ELECTRONICS, INC. Increase (Decrease) in Accounts Receivable |
Metric Details
- Metric
- Increase (Decrease) in Accounts Receivable (IncreaseDecreaseInAccountsReceivable)
- Taxonomy
- us-gaap
- Units tracked
- USD
- Frequency coverage
- quarterly and annual
- History range
- 31 Dec 2021 - 31 Mar 2025
- Facts on this page
- 7
- Description
- The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Increase (Decrease) in Accounts Receivable, Quarterly (USD)
Increase (Decrease) in Accounts Receivable, YoY Quarterly Change (%)
Increase (Decrease) in Accounts Receivable, Annual (USD)
Increase (Decrease) in Accounts Receivable, YoY Annual Change (%)
SpringWorks Therapeutics, Inc. Quarterly Increase (Decrease) in Accounts Receivable (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2025 | $5,891,000 | -$15,490,000 | -161% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 09 May 2025 | 2025 | Q1 | |
| Q1 2024 | $9,599,000 | +$9,599,000 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 09 May 2025 | 2025 | Q1 | ||
| Q1 2023 | $0 | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 02 May 2024 | 2024 | Q1 |
SpringWorks Therapeutics, Inc. Annual Increase (Decrease) in Accounts Receivable (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | $40,308,000 | +$34,378,000 | +580% | 01 Jan 2024 | 31 Dec 2024 | 10-K | 20 Feb 2025 | 2024 | FY |
| 2023 | $5,930,000 | +$5,930,000 | 01 Jan 2023 | 31 Dec 2023 | 10-K | 20 Feb 2025 | 2024 | FY | |
| 2022 | $0 | $0 | 01 Jan 2022 | 31 Dec 2022 | 10-K | 20 Feb 2025 | 2024 | FY | |
| 2021 | $0 | 01 Jan 2021 | 31 Dec 2021 | 10-K | 27 Feb 2024 | 2023 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.